<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Neomycin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00994</strong>&#160; (APRD00013)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00994/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00994/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00994.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00994.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00994.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00994.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00994.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00994">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Neomycin Sulfate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000472/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000472/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: OIXVKQDWLFHVGR-CITJEJKVSA-N</li>
              <li>Monoisotopic Mass: 712.27966483</li>
              <li>Average Mass: 712.722</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000472">DBSALT000472</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Myacyne</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mycifradin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Myciguent</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neo-Fradin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neo-Rx</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neobiotic</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nivemycin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Cortisporin</td><td>bacitracin zinc + hydrocortisone + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Cortomycin</td><td>Hydrocortisone + Polymyxin B Sulfate + Neomycin</td></tr><tr><td>Diosporin ointment</td><td>bacitracin zinc + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Maxitrol</td><td>dexamethasone + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Methedex</td><td>Polymyxin B Sulfate + Neomycin + Dexamethasone</td></tr><tr><td>Mycitracin Triple Antibiotic</td><td>bacitracin + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Neo-Decadron</td><td>dexamethasone phosphate + neomycin sulfate</td></tr><tr><td>Neo-Medrol Acne Lotion</td><td>aluminum chlorohydrate + methylprednisolone acetate + neomycin sulfate + sulfur</td></tr><tr><td>NEO-POLY-BAC</td><td>Bacitracin + Polymyxin B Sulfate + Neomycin</td></tr><tr><td>NEO-POLY-DEX</td><td>Polymyxin B Sulfate + Neomycin + Dexamethasone</td></tr><tr><td>NEO-POLYCIN</td><td>Bacitracin + Hydrocortisone + Polymyxin B Sulfate + Neomycin</td></tr><tr><td>NEOCIDIN</td><td>Gramicidin D + Polymyxin B Sulfate + Neomycin</td></tr><tr><td>Neocidin</td><td>Gramicidin D + Polymyxin B Sulfate + Neomycin</td></tr><tr><td>Neosporin Antibiotic Cream</td><td>gramicidin + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Neosporin Eye-Ear Solution</td><td>gramicidin + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Neosporin Irrigating Solution</td><td>neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Neosporin Ointment</td><td>bacitracin zinc + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Neosporin Ophthalmic Ointment</td><td>bacitracin zinc + neomycin sulfate + polymyxin B sulfate</td></tr><tr><td>Neosulf</td><td>neomycin sulfate + sulfamethazine + sulfathiazole</td></tr><tr><td>Triple Antibiotic Plus Ointment</td><td>neomycin sulfate + sulfamerazine sodium + sulfamethazine sodium + sulfathiazole sodium</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/aminoglycosides">Aminoglycosides</a></li>
<li><a href="/mesh/antibiotics">Antibiotics</a></li></ul></td></tr><tr><th>CAS number</th><td>1404-04-2</td></tr><tr><th>Weight</th><td>Average: 614.6437<br>Monoisotopic: 614.312285588</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>46</sub>N<sub>6</sub>O<sub>13</sub></td></tr><tr><th>InChI Key</th><td>PGBHMTALBVVCIT-VCIWKGPPSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Amino Sugars</td></tr><tr><th>Direct parent</th><td>Aminocyclitol Glycosides</td></tr><tr><th>Alternative parents</th><td>Mixed Pentose/Hexose Trisaccharides; O-glycosyl Compounds; Aminocyclitols and Derivatives; Cyclohexanols; Oxanes; Oxolanes; Tetrahydrofurans; 1,2-Diols; 1,2-Aminoalcohols; Polyamines; Primary Alcohols; Acetals; Monoalkylamines</td></tr><tr><th>Substituents</th><td>trisaccharide; o-glycosyl compound; glycosyl compound; aminocyclitol derivative; cyclitol derivative; cyclohexanol; oxane; oxolane; cyclic alcohol; tetrahydrofuran; secondary alcohol; 1,2-aminoalcohol; 1,2-diol; ether; primary alcohol; acetal; polyamine; alcohol; amine; organonitrogen compound; primary aliphatic amine; primary amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidially linked to a carbohydrate moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC). </td></tr><tr><th>Pharmacodynamics</th><td>Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.</td></tr><tr><th>Mechanism of action</th><td>Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.</td></tr><tr><th>Absorption</th><td>Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, may be between 0% and 30%.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Neomycin undergoes negligible biotransformation after parenteral administration.</p></td></tr><tr><th>Route of elimination</th><td>The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function.</td></tr><tr><th>Half life</th><td>2 to 3 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild reversible. Neomycin is the most toxic aminoglycoside agent, which is thought to be due to its large number of cationic amino groups. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear causing irreversible damage to hair cells in the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing loss is followed by low frequency hearing loss. Further toxicity may cause retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance. </td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Neomycin Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8617</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9659</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7502</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5164</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8023</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8764</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7886</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8231</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8041</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6473</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9157</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9147</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9034</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9471</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8446</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6934
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9505
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8587
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.4850 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9728
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.81
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>X gen pharmaceuticals inc</li>
<li>Pharmacia and upjohn co</li>
<li>Pfizer laboratories div pfizer inc</li>
<li>Bristol myers squibb co</li>
<li>Lannett co inc</li>
<li>Eli lilly and co</li>
<li>Oman pharmaceutical products co llc</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li>Amend</li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.draxispharma.com">Draxis Specialty Pharmaceuticals Inc.</a></li>
<li><a href="http://www.hitechpharm.com">Hi Tech Pharmacal Co. Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.x-gen.us">X-Gen Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Dressing</td><td>Topical</td><td></td></tr><tr><td>Ointment</td><td>Ophthalmic</td><td></td></tr><tr><td>Solution / drops</td><td>Ophthalmic</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00493">Cefotaxime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01330">Cefotetan</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01331">Cefoxitin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00438">Ceftazidime</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01212">Ceftriaxone</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB01111">Colistimethate</a></td><td>Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01607">Ticarcillin</a></td><td>Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>